A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Trial Profile

A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Navitoclax (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 28 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2011 Planned End Date changed from 1 May 2012 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 05 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top